CEST MRI has emerged as a sensitive contrast mechanism for several metabolites such as glucose, glycogen, creatine and glutamate, as well as tissue pH. It has promising applications in a host of disorders including acute stroke, epilepsy and tumor. As we make the transition from CEST-weighted MRI toward quantitative in vivo CEST imaging for improved characterization of the underlying physiology, it is helpful to review persistent progress in the field of CEST imaging from equations, cells, rodents and patients.
This abstract and the presentation materials are available to members only; a login is required.